CAR T cells designed to express CD19 have shown unprecedented clinical success in otherwise refractory patients suffering from ALL or diffuse large B-cell lymphoma, frequently accompanied by severe adverse toxicity. Here, CD19 is linked to acute lymphoblastic leukemia.